- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01769313
A Single Centre Study to Analyze Cataract Surgery Following Femtosecond Laser-Assisted and Manual Cataract Surgery
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A detailed pre-operative examination will ensure that every interested and willing patient fulfills the inclusion criteria of this study. For the proposed contralateral eye study between 30 and 35 patients will be enrolled whereas one eye will randomized undergo a manual cataract surgery and the other one a laser assisted cataract surgery. In total between 60 and 70 eyes will be included in the study. Pre-operative examinations are included to confirm to the clinical practice. Examinations on the day of surgery and any occurrence during the procedure are also listed. Post-operative examinations, which should document any occurrence, the outcome of and possible differences between the treatment techniques, are to be carried out after 1 day, 1 week, 1 month, 3 months and 6 months. After 6 month a final report including the study results will be produced.
The study is carried out in compliance with MEDDEV 2.7.1 Evaluation of Clinical Data: A Guide for Manufacturers and Notified Bodies, ICH E6 (R1) Good Clinical Practice (GCP), Declaration of Helsinki as well as the applicable local regulations such as notification requirements and current order of profession of the primary investigators.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Heidelberg, Germany, 69120
- Universitäts-Augenklinik Heidelberg
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clear corneal media
- Patients must be at least 18 years of age
- Patients must have read, understood and signed the Patient Information
- Patients are willing and able to return for follow-up examinations
- Topographic Astigmatism ≤ 1.5 dpt
- Patient will get a monofocal IOL (Envista) implanted
Exclusion Criteria:
- On a keratometric map of the cornea, the minimal and maximal K-values of the central 3mm zone must not differ by more than 5D (exclusion criterium for Group A only)
- The maximum K- value may not exceed 60D, the minimal value may not be smaller than 37D (exclusion criterium for Group A only)
- Corneal disease or pathology, such as corneal scaring or opacity, that precludes transmission of laser wavelength or that distorts laser light (exclusion criteria for Group A only)
- Subjects with a poorly dilating pupil or other defect of the pupil that prevents the iris from adequate retraction peripherally
- Lens/zonular instability such as, but not restricted to, Marfan's Syndrome, Pseudoexfoliation Syndrome, etc.
- Manifest Glaucoma
- Patients presenting a clear lens (clear lens exchange)
- Previous intraocular or corneal surgery of any kind, including any type of surgery for either refractive or therapeutic purposes in either eye
- Known sensitivity to planned concomitant medications
- Patients with disorders of the ocular muscle, such as nystagmus or strabismus
- Patients with keratoconus or keratectasia
- Patients with connective tissue weakness
- Patients who are blind on one eye
- Subjects who are immune compromised or carrying diagnosis of connective tissue disease, clinically significant atopic disease, insulin dependent diabetes mellitus, autoimmune diseases, ocular herpes zoster or simplex, endocrine diseases, lupus, rheumatoid arthritis, collagenosis and other acute or chronic illnesses that will increase the risk to the subject or confound the outcomes of this study.
- Abnormal examination results from slit lamp, fundus examination or IOL Master, age related changes are acceptable
- Abnormal examination results from Orbscan (exclusion criteria for Group A only; , age related changes are acceptable
- Patients who are pregnant or nursing
- Patients who do not give informed consent
- Patients with concentration disorders, epilepsy and other complicating diseases
- Patients regularly taking medicines that could influence the result of the treatment
- Patients who are participating in another ophthalmological clinical study
- Patients with an anterior chamber depth (ACD) < 1.5 mm or ACD > 4.8 mm as measured as from the corneal endothelium.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A
In Group A the anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery
|
The anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery
|
Active Comparator: Group B
Group B acts as a control group where the capsulotomy as well as the lens fragmentation is performed manually.
|
The anterior capsulotomy and lens fragmentation will be performed manually.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ΔROverlap is different between Group A and Group B
Time Frame: 6 Month postoeprative
|
• The decentration, ΔROverlap, between implanted IOL and capsulotomy aperture is different in Group A as compared to Group B. p<0.05 will be considered statistically significant. The study end point will be determined for all follow-up examination periods; the purpose criterion should be achieved by the 6 month examination at the latest. Goal:To evaluate a significant difference (p<0.05) of ΔROverlap between Group A and Group B |
6 Month postoeprative
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ΔELP is different between Group A and Group B
Time Frame: 6 months postoperative
|
• The difference, Δ Flare, between preoperative and postoperative is different for Group A as compared to group B. p<0.05 will be considered statistically significant. The study end point will be determined 1-Day and 1-Week follow-up examination periods; the purpose criterion should be achieved by the 1-Week follow-up examination at the latest. Goal: To evaluate a significant difference (p<0.05) of Δ Flare between Group A and Group B |
6 months postoperative
|
ΔFlare is different between Group A and Group B
Time Frame: 6 months postoperative
|
• The difference, Δ Flare, between preoperative and postoperative is different for Group A as compared to group B. p<0.05 will be considered statistically significant. The study end point will be determined 1-Day and 1-Week follow-up examination periods; the purpose criterion should be achieved by the 1-Week follow-up examination at the latest. Goal: To evaluate a significant difference (p<0.05) of Δ Flare between Group A and Group B |
6 months postoperative
|
SEQ Prediction Error is different between Group A and Group B
Time Frame: 6 months postoperatvie
|
• The difference, SEQ Prediction Error, between target refraction SEQ and actual SEQ is different in Group A as compared to Group B. p<0.05 will be considered statistically significant. The study end point will be determined for all follow-up examination periods, the purpose criterion should be achieved by the 6 month examination at the latest. Goal: To evaluate a significant difference (p<0.05) of the SEQ Prediction Error between Group A and Group B |
6 months postoperatvie
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gerd U Auffarth, Prof. Dr., Universitäts-Augenklinik Heidelberg
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1202
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cataract
-
Fundación Pública Andaluza para la Investigación...CompletedCataract | Cataract Mature | Cataract, Nuclear
-
Johannes Kepler University of LinzCompletedCataract Complicated | Cataract Complications OperationsAustria
-
Gemini Eye ClinicRecruitingBilateral Cataract | Unilateral CataractCzechia
-
Universitaire Ziekenhuizen KU LeuvenLaboratoires TheaRecruiting
-
Omer Othman AbdullahCompletedCongenital Cataract | Pediatric CataractIraq
-
Yonsei UniversityCompletedCataract PatientsKorea, Republic of
-
Johannes Kepler University of LinzRecruitingAphakia | Secondary Cataract Surgery | Complicated Cataract SurgeryAustria
-
Advanced Center for Eyecare GlobalNot yet recruiting
-
Vienna Institute for Research in Ocular SurgeryRecruiting
-
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityNot yet recruitingCataract ExtractionChina
Clinical Trials on Laser-assisted cataract surgery
-
Guy's and St Thomas' NHS Foundation TrustCompletedCataract | Surgery
-
University Hospital, BordeauxCompleted
-
Medical University of ViennaCompleted
-
Singapore Eye Research InstituteUnknownVisual OutcomesSingapore
-
Wenzhou Medical UniversityCompleted
-
University of Texas Southwestern Medical CenterCompletedIncipient Cataract | Senile Nuclear SclerosisUnited States
-
Kenneth J RosenthalJohnson & Johnson Surgical Vision, Inc.Not yet recruitingCataract | AstigmatismUnited States
-
Steve H. Linn, ODCompletedCortical Cataract | Posterior Subcapsular Cataract | Nuclear Sclerosis of the LensUnited States
-
Technolas Perfect Vision GmbHCompletedCataractCzech Republic, India
-
Technolas Perfect Vision GmbHCompletedCataractCzech Republic, India